Literature DB >> 24206762

Persistent exudative retinal detachment after photodynamic therapy and intravitreal bevacizumab injection for multiple retinal capillary hemangiomas in a patient with von Hippel-Lindau disease.

Fang-Yi Tsai1, Ling-Ing Lau2, Shih-Jen Chen3, Fenq-Lih Lee3, Shui-Mei Lee3.   

Abstract

Photodynamic therapy (PDT) has been used in treating peripheral retinal capillary hemangioma (RCH) with satisfactory results. We report a rare case of von Hippel-Lindau (VHL) disease with three large peripheral RCHs, treated with PDT and intravitreal bevacizumab injection (IVB), who developed persistent bullous exudative retinal detachment (RD) despite significant tumor regression. The patient is a sporadic case of VHL disease, with a de novo nonsense mutation in codon 161 with C → T transition at nucleotide position 694 of the VHL gene. Multiple RCHs were noted in both eyes. Four small RCHs were found in the left eye and were treated with laser photocoagulation. Three large RCHs in the peripheral retina of the right eye were complicated with cystoid macular edema and subretinal fluid accumulation. The RCHs were treated with PDT combined with IVB, and bullous exudative RD developed on the second day after treatment. Three months after PDT, the tumors had regressed significantly, but exudative RD persisted, despite multiple IVB and intravitreal triamcinolone acetonide injection (IVTA). External drainage with sclera buckling, IVB, and IVTA were performed, and the retina attached after surgical intervention. The application of PDT in the treatment of RCHs and its possible complications are discussed.
Copyright © 2013. Published by Elsevier B.V.

Entities:  

Keywords:  exudative retinal detachment; photodynamic therapy; retinal capillary hemangioma; von Hippel–Lindau

Mesh:

Substances:

Year:  2013        PMID: 24206762     DOI: 10.1016/j.jcma.2013.09.001

Source DB:  PubMed          Journal:  J Chin Med Assoc        ISSN: 1726-4901            Impact factor:   2.743


  4 in total

1.  Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease.

Authors:  Virginia Albiñana; Rosa María Jiménez Escribano; Isabel Soler; Luis Rodríguez Padial; Lucia Recio-Poveda; Karina Villar Gómez de Las Heras; Luisa María Botella
Journal:  Orphanet J Rare Dis       Date:  2017-06-29       Impact factor: 4.123

Review 2.  Von Hippel-Lindau Disease: Current Challenges and Future Prospects.

Authors:  Sven Gläsker; Evelynn Vergauwen; Christian A Koch; Alexander Kutikov; Alexander O Vortmeyer
Journal:  Onco Targets Ther       Date:  2020-06-16       Impact factor: 4.147

3.  Intravitreal Triamcinolone Acetonide in Von Hippel-Lindau Patient with Novel Mutation.

Authors:  Maryam Bunajem; Moustafa Magliyah; Yahya Alzahrani
Journal:  Middle East Afr J Ophthalmol       Date:  2020-10-30

4.  Clinical characters and treatments of retinal vasoproliferative tumors.

Authors:  Yi-Ming Huang; Shih-Jen Chen
Journal:  Taiwan J Ophthalmol       Date:  2016-05-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.